PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2112675-0 1990 Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis. Pravastatin 10-28 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 49-96 2112675-1 1990 The effect of Pravastatin sodium (CS-514), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA R) on very-low-density lipoprotein (VLDL) composition and kinetics was studied in normal and experimental nephrotic rats under fasting conditions. Pravastatin 14-32 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 111-120 2112675-1 1990 The effect of Pravastatin sodium (CS-514), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA R) on very-low-density lipoprotein (VLDL) composition and kinetics was studied in normal and experimental nephrotic rats under fasting conditions. Pravastatin 34-40 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 111-120 2112675-2 1990 Nephrotic rats, induced by a single intraperitoneal injection of puromycin aminonucleoside (100 mg/kg body weight), had significantly higher plasma lipids and apoprotein (apo) B concentrations than controls. Puromycin Aminonucleoside 65-90 apolipoprotein B Rattus norvegicus 159-177 2112675-6 1990 TG, cholesterol, phospholipid, and apo B concentrations in nephrotic VLDL were significantly reduced by Pravastatin treatment, whereas only TG was decreased in control VLDL. Pravastatin 104-115 apolipoprotein B Rattus norvegicus 35-40 2112675-7 1990 Pravastatin reduced the apo B 100 + 95/48 ratio in nephrotic VLDL. Pravastatin 0-11 apolipoprotein B Rattus norvegicus 24-33